Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

被引：28

作者：

Rossi, Ernesto ^{[1
]}

Maiorano, Brigida Anna ^{[1
]}

Pagliara, Monica Maria ^{[2
]}

Sammarco, Maria Grazia ^{[2
]}

Dosa, Tommaso ^{[1
]}

Martini, Maurizio ^{[3
]}

Rindi, Guido ^{[3
]}

Bria, Emilio ^{[1
]}

Blasi, Maria Antonietta ^{[2
]}

Tortora, Giampaolo ^{[1
]}

Schinzari, Giovanni ^{[1
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Med Oncol, Rome, Italy

[2] Fdn Policlin Univ A Gemelli IRCCS, Ophtalmol, Rome, Italy

[3] Fdn Policlin Univ A Gemelli IRCCS, Pathol, Rome, Italy

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

BRAF; MEK; target therapy; conjunctival; melanoma; NRAS MUTATIONS; MEK INHIBITION; HARBOR BRAF; SURVIVAL; PHASE-3;

D O I：

10.3389/fonc.2019.00232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.

引用

页数：5

共 50 条

[1] Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Menzies, Alexander M.
Long, Georgina V.
[J]. CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2035 - 2043
[2] Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma
Kim, Jenna May
Weiss, Sarah
Sinard, John H.
Pointdujour-Lim, Renelle
[J]. OCULAR ONCOLOGY AND PATHOLOGY, 2020, 6 (01) : 35 - 38
[3] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto
Pier Francesco Ferrucci
Rosalie Fisher
Michele Del Vecchio
Victoria Atkinson
Henrik Schmidt
Jacob Schachter
Paola Queirolo
Georgina V. Long
Anna Maria Di Giacomo
Inge Marie Svane
Michal Lotem
Gil Bar-Sela
Felix Couture
Bijoyesh Mookerjee
Razi Ghori
Nageatte Ibrahim
Blanca Homet Moreno
Antoni Ribas
[J]. Nature Medicine, 2019, 25 : 941 - 946
[4] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, Paolo Antonio
Ferrucci, Pier Francesco
Fisher, Rosalie
Del Vecchio, Michele
Atkinson, Victoria
Schmidt, Henrik
Schachter, Jacob
Queirolo, Paola
Long, Georgina V.
Di Giacomo, Anna Maria
Svane, Inge Marie
Lotem, Michal
Bar-Sela, Gil
Couture, Felix
Mookerjee, Bijoyesh
Ghori, Razi
Ibrahim, Nageatte
Moreno, Blanca Homet
Ribas, Antoni
[J]. NATURE MEDICINE, 2019, 25 (06) : 941 - +
[5] Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
Rossi, Ernesto
Schinzari, Giovanni
Cellini, Francesco
Balducci, Mario
Pasqualoni, Mariangela
Maiorano, Brigida Anna
Fionda, Bruno
Longo, Silvia
Deodato, Francesco
Di Stefani, Alessandro
Peris, Ketty
Gambacorta, Maria Antonietta
Tortora, Giampaolo
[J]. BIOMEDICINES, 2023, 11 (02)
[6] Dabrafenib plus trametinib in BRAF K601E-mutant melanoma
Rogiers, A.
Thomas, D.
Vander Borght, S.
van den Oord, J. J.
Bechter, O.
Dewaele, M.
Rambow, F.
Marine, J. -C.
Wolter, P.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (02) : 421 - 422
[7] VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report
Gunaratnam, Cadric
Muzicenco, Olga
Sivagurunathan, Premala
Franzco, Michael Hogden
[J]. JOURNAL OF SURGICAL CASE REPORTS, 2024, 2024 (03):
[8] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long
Carina Fung
Alexander M. Menzies
Gulietta M. Pupo
Matteo S. Carlino
Jessica Hyman
Hamideh Shahheydari
Varsha Tembe
John F. Thompson
Robyn P. Saw
Julie Howle
Nicholas K. Hayward
Peter Johansson
Richard A. Scolyer
Richard F. Kefford
Helen Rizos
[J]. Nature Communications, 5
[9] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Long, Georgina V.
Fung, Carina
Menzies, Alexander M.
Pupo, Gulietta M.
Carlino, Matteo S.
Hyman, Jessica
Shahheydari, Hamideh
Tembe, Varsha
Thompson, John F.
Saw, Robyn P.
Howle, Julie
Hayward, Nicholas K.
Johansson, Peter
Scolyer, Richard A.
Kefford, Richard F.
Rizos, Helen
[J]. NATURE COMMUNICATIONS, 2014, 5
[10] Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
Moreno, Blanca Homet
Mok, Stephen
Comin-Anduix, Begonya
Hu-Lieskovan, Siwen
Ribas, Antoni
[J]. ONCOIMMUNOLOGY, 2016, 5 (07):

← 1 2 3 4 5 →